ITOS Form 4: Options and RSUs Settled for $10.047 Cash Plus CVRs

Rhea-AI Filing Summary

Form 4 from reporting person "Call Matthew" (Chief Operating Officer) reports insider dispositions tied to iTeos Therapeutics' merger. On 08/29/2025 the reporting person disposed of 161,898 shares of common stock, resulting in 0 shares beneficially owned after the transaction. Each issued and outstanding share was canceled at the merger Effective Time and converted into $10.047 in cash per share plus one non-transferable CVR per share. The filing explains that certain restricted stock units and unvested options accelerated and were cancelled; In-the-Money Options (exercise price < $10.047) were settled for cash equal to the excess of $10.047 over the exercise price times the underlying shares, plus one CVR per underlying share. The Form 4 lists multiple canceled stock options with exercise prices of $7.05, $4.24 and $2.95 for specified share amounts, all resulting in zero common shares held post-merger.

Positive

• All issued shares were converted into a known cash amount of $10.047 per share, providing definitive consideration to holders
• Holders of in-the-money options received cash equal to the spread (Cash Amount minus exercise price) times underlying shares, plus one CVR per share
• Accelerated vesting applied to applicable restricted stock units and options, enabling immediate settlement at the Effective Time

Negative

• Reporting person holds 0 shares following the transaction, eliminating direct equity ownership in the company post-merger

Insights

Corporate Governance Expert

TL;DR: Insider holdings were fully converted in the merger for cash and CVRs; accelerated awards were settled per merger terms.

The filing documents a standard change-in-control settlement process: outstanding restricted stock units and unvested options held by the reporting officer accelerated and were settled at the merger Effective Time. Issued shares were canceled and converted into $10.047 cash per share plus a CVR, and in-the-money options were cashed out based on the spread over their exercise prices. The result is a clean disposition with no remaining beneficial ownership reported for this officer.

M&A / Compensation Specialist

TL;DR: Merger consideration included cash and contingent value rights; equity awards were treated consistently with the Merger Agreement.

The disclosure details treatment of equity awards under the Merger Agreement: Accelerated Vesting Restricted Stock Units became vested then canceled for cash equal to the per-share cash consideration plus a CVR, and In-the-Money Options were canceled for cash equal to the per-share spread times underlying shares plus CVRs. The Form 4 enumerates specific option pools canceled at exercise prices of $7.05, $4.24 and $2.95 with stated underlying share counts, facilitating straightforward payout calculations for affected holders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Call Matthew

(Last) (First) (Middle)

C/O ITEOS THERAPEUTICS, INC.

321 ARSENAL STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		U(1)(2)(3)		161,898	D	(1)(2)(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.05	08/29/2025		D(4)			9,063	(4)(5)	(4)(5)	Common Stock	9,063	(4)(5)	0	D
Stock Option (Right to Buy)	$7.05	08/29/2025		D(4)			135,937	(4)(5)	(4)(5)	Common Stock	135,937	(4)(5)	0	D
Stock Option (Right to Buy)	$2.95	08/29/2025		D(5)			41,694	(5)	(5)	Common Stock	41,694	(5)	0	D
Stock Option (Right to Buy)	$2.95	08/29/2025		D(5)			66,170	(5)	(5)	Common Stock	66,170	(5)	0	D
Stock Option (Right to Buy)	$4.24	08/29/2025		D(5)			17,074	(5)	(5)	Common Stock	17,074	(5)	0	D
Stock Option (Right to Buy)	$4.24	08/29/2025		D(5)			146,835	(5)	(5)	Common Stock	146,835	(5)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes.

2. The amount reported in Column 4 includes 68,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the "Committee") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with,

3. (Continued from footnote 2) or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR.

4. Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full.

5. In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.

	/s/ Adi Osovsky, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the iTeos (ITOS) Form 4 report for 08/29/2025?

The Form 4 reports disposition of 161,898 common shares and cancellation/settlement of multiple stock options and restricted stock units in connection with the merger.

How much cash was paid per iTeos share at the merger Effective Time?

$10.047 in cash per issued and outstanding share, plus one non-transferable CVR per share.

How were in-the-money options treated in the merger?

In-the-money options (exercise price less than $10.047) were canceled and the holders received cash equal to (Cash Amount minus exercise price) times the number of underlying shares, plus one CVR per underlying share.

Which option exercise prices and amounts are disclosed in the Form 4?

The filing lists canceled stock options with exercise prices of $7.05 (9,063 and 135,937 shares), $2.95 (41,694 and 66,170 shares), and $4.24 (17,074 and 146,835 shares).

Does the reporting person retain any beneficial ownership after the transaction?

No. The Form 4 reports 0 shares beneficially owned by the reporting person following the reported transactions.